NCOA3 and ovarian carcinoma: In addition, immunohistochemistry in ovarian carcinoma tissue samples revealed that strong NCOA3 expression was associated with higher stages (i.e., stages III and IV) and worse patient outcomes (HR = 1.349, P = 0.015 in a multivariate analysis for OS) [102].